Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-09-2013 | Original Paper

Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma

Authors: Lokman Ayaz, Aysegül Görür, Hatice Yıldırım Yaroğlu, Cengiz Özcan, Lülüfer Tamer

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2013

Abstract

Purpose

Altered microRNA (miRNA) expression has been found in many cancers, including lung, breast, prostate, bladder and colorectal cancer. Many recent studies have demonstrated that aberrant plasma miRNAs were also found in various types of cancers. However, the alteration in plasma miRNA expressions in laryngeal squamous cell carcinoma (LSCC) remains unclear. The present study aimed to investigate the alterations in plasma miRNAs in LSCC.

Methods

In the present study, the expression profiles of 738 miRNAs in plasma from 20 patients and 44 healthy subjects were evaluated using high-throughput real-time quantitative polymerase chain reaction.

Results

Our results demonstrated that expression levels of 17 miRNAs were significantly upregulated in patients with LSCCs when compared to control group (p < 0.05). Expression levels of nine miRNAs were found significantly downregulated in LSCC patients (p < 0.05). In addition, 17 miRNAs were expressed only in LSCC group, and five of these miRNAs (miR-331-3p, 603, 1303, 660-5p and 212-3p) are LSCC specific and never seen before in plasma of any human subject.

Conclusion

In conclusion, our study suggests that detecting these LSCC-specific miRNAs in plasma might serve as novel noninvasive biomarkers for LSCC.

Available only for authorised users

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297CrossRefPubMed

Bian K, Fan J, Zhang X, Yang XW, Zhu HY, Wang L, Sun JY, Meng YL, Cui PC, Cheng SY, Zhang J, Zhao J, Yang AG, Zhang R (2012) MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS Lett 23:804–809CrossRef

Bo J, Yang G, Huo K, Jiang H, Zhang L, Liu D, Huang Y (2011) MicroRNA-203 suppresses bladder cancer development by repressing bcl-w expression. FEBS J 278:786–792CrossRefPubMed

Brase JC, Johannes M, Schlomm T (2010) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128:608–616CrossRef

Bueno MJ, Pérez de Castro I, Gómez de Cedrón M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernández-Piqueras J, Malumbres M (2008) Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCRABL1 oncogene expression. Cancer Cell 13:496–506CrossRefPubMed

Cai K, Wang Y, Bao X (2011) MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma. J Exp Clin Cancer Res 30:73. doi:10.1186/1756-9966-30-73 CrossRefPubMed

Calin GA, Dumitru CD, Shimizu M (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci (USA) 99:15524–15529CrossRef

Cao P, Zhou L, Zhang J, Zheng F, Wang H, Ma D, Tian J (2013) Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck 35(5):720–728CrossRefPubMed

Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM, Yang J (2012) A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 72:1443–1452CrossRefPubMed

Chiang Y, Song Y, Wang Z, Chen Y, Yue Z, Xu H, Xing Cand Liu Z (2011) Aberrant expression of miR-203 and its clinical significance in gastric and colorectal cancers. J Gastrointest Surg 15:63–70CrossRefPubMed

Chu EA, Kim YJ (2008) Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol Clin N Am 41:673–695CrossRef

Doebele C, Bonauer A, Fischer A, Scholz A, Reiss Y, Urbich C, Hofmann WK, Zeiher AM, Dimmeler S (2010) Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood 115(23):4944–4950CrossRefPubMed

Dosemeci M, Gokmen I, Unsal M, Hayes RB, Blair A (1997) Tobacco, alcohol use, and risks of laryngeal and lung cancer by subsite and histologic type in Turkey. Cancer Causes Control 8(5):729–737CrossRefPubMed

Elci OA, Elci MA, Blair A, Dosemeci M (2003) Risk of laryngeal cancer by occupational chemical exposure in Turkey. J Occup Environ Med 45:1100–1106CrossRefPubMed

Farid WR, Pan Q, van der Meer AJ, de Ruiter PE, Ramakrishnaiah V, de Jonge J, Kwekkeboom J, Janssen HL, Metselaar HJ, Tilanus HW, Kazemier G, van der Laan LJ (2012) Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl 18(3):290–297CrossRefPubMed

Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811CrossRefPubMed

Freedman JE, Ercan B, Morin KM, Liu C, Tamer L, Ayaz L, Kanadasi M, Cicek D, Ali Seyhan Ihsan A, Eker Akilli R, Camci C, Cengiz B, Oztuzcu S, Tanriverdi K (2012) The distribution of circulating microRNA and their relation to coronary disease. F1000 Research 1:50

Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J (2010) MiR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 31:766–776CrossRefPubMed

Hardisson D (2003) Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 260:502–508CrossRefPubMed

Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC (2012) Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 130(6):1378–1386CrossRefPubMed

Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251:499–505CrossRefPubMed

Huang Z, Huang D, Ni S (2010) Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127:118–126CrossRefPubMed

Huang JJ, Yu J, Li JY, Liu YT, Zhong RQ (2012) Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med Oncol 29(4):2402–2408CrossRefPubMed

Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, Shi W, Perez-Ordonez B, Jurisica I, O’Sullivan B, Waldron J, Gullane P, Cummings B, Liu FF (2010) Comprehensive microRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 16:1129–1139CrossRefPubMed

Kosaka N, Iguchi H, Ochiya T (2010) Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101:2087–2092CrossRefPubMed

Lawrie CH, Gal S, Dunlop HM (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141:672–675CrossRefPubMed

Li J, Chen Y, Zhao J, Kong F, Zhang Y (2011) MiR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett 304:52–59CrossRefPubMed

Lin T, Dong W, Huang J, Pan Q, Fan X, Zhang C, Huang L (2009) MicroRNA-143 as a tumor suppressor for bladder cancer. J Urol 181:1372–1380CrossRefPubMed

Liu J, Lei DP, Jin T, Zhao XN, Li G, Pan XL (2011) Altered expression of miR-21 and PTEN in human laryngeal and hypopharyngeal squamous cell carcinomas. Asian Pac J Cancer Prev 12(10):2653–2657PubMed

Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449:682–688CrossRefPubMed

Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, Vandesompele J (2009) A novel and universal method for miRNA RT-qPCR data normalization. Genome Biol 10:R64CrossRefPubMed

Mitchell PS, Parkin RK, Kroh EM (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci (USA) 105:10513–10518CrossRef

Morimura R, Komatsu S, Ichikawa D, Takeshita H, Tsujiur M, Nagata H, Konishi H, Shiozaki A, Ikoma H, Okamoto K, Ochiai T, Taniguchi H, Otsuji E (2011) Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 105(11):1733–1740

Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:2002–2007CrossRef

Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB (2007) MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther 7:1288–1296

Saini S, Arora S, Majid S, Shahryari V, Chen Y, Deng G, Yamamura S, Ueno K, Dahiya R (2011a) Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev Res (Phila) 4:1698–1709CrossRef

Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, Chen Y, Deng G, Tanaka Y, Dahiya R (2011b) Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res 17:5287–5298CrossRefPubMed

Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Guarnera M, Liao J, Chou A, Lu CL, Jiang Z, Fang H, Katz RL, Jiang F (2011) Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 91:579–587CrossRefPubMed

Siegel R, Ward E, Brawley Q (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236CrossRefPubMed

Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110:13–21CrossRefPubMed

Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, Zamboni G, Maciejewski R (2012) Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. Int J Cancer. doi:10.1002/ijc.27840 PubMed

Turchinovich A, Weiz L, Langheinz A (2011) Characterization of extracellular circulating microRNA. Nucleic Acids Res 39:7223–7233CrossRefPubMed

Wang F, Zheng Z, Guo J, Ding X (2010a) Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 119(3):586–593CrossRefPubMed

Wang HJ, Zhang PJ, Chen WJ, Feng D, Jia YH, Xie LX (2010b) Four serum microRNAs identified as diagnostic biomarkers of sepsis. J Trauma Acute Care Surg 73(4):850–854CrossRef

Yamane K, Jinnin M, Etoh T, Kobayashi Y, Shimozono N, Fukushima S, Masuguchi S, Maruo K, Inoue Y, Ishihara T, Aoi J, Oike Y, Ihn H (2013) Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. J Mol Med (Berl) 91(1):69–81CrossRef

Yuan Y, Zeng ZY, Liu XH, Gong DJ, Tao J, Cheng HZ, Huang SD (2011) MicroRNA-203 inhibits cell proliferation by repressing DNp63 expression in human esophageal squamous cell carcinoma. BMC Cancer 11:57CrossRefPubMed

Zamore PD, Haley B (2005) Ribo-gnome: the big world of small RNAs. Science 309:1519–1524CrossRefPubMed

Zhang B, Pan X, Cobb GP, Anderson TA (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302:1–12CrossRefPubMed

Zhang C, Wang C, Chen X (2010) Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 56:1871–1879CrossRefPubMed

Title: Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma
Authors: Lokman Ayaz
Aysegül Görür
Hatice Yıldırım Yaroğlu
Cengiz Özcan
Lülüfer Tamer
Publication date: 01-09-2013
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 9/2013
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-013-1469-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2013

Generation and characterization of virus-free reprogrammed melanoma cells by the piggyBac transposon

Novel immunodominant epitopes derived from MAGE-A3 and its significance in serological diagnosis of gastric cancer

A patient-derived xenograft mouse model generated from primary cultured cells recapitulates patient tumors phenotypically and genetically

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer

Expression and clinical role of small glutamine-rich tetratricopeptide repeat (TPR)-containing protein alpha (SGTA) as a novel cell cycle protein in NSCLC

Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials